Antiviral therapy for hepatitis B virus associated hepatic failure

Hepatobiliary and Pancreatic Diseases International

Volumn 8, Issue 1, 2009, Pages 17-24

  Wang, Yu Ming ^a   Tang, Ying Zi ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antiviral therapy; Fulminant hepatitis; Hepatitis B virus; Orthotopic liver transplantation

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; CORTICOSTEROID; ENTECAVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; NUCLEOSIDE ANALOG; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; FLUSHING; GENE MUTATION; GRAFT INFECTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PROGNOSIS; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SURVIVAL RATE; THORAX PAIN;

ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HUMANS; LIVER FAILURE, ACUTE;

EID: 60549105185     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-1745.
2. Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004;351:2832-2838.
3. Tsang SW, Chan HL, Leung NW, Chau TN, Lai ST, Chan FK, et al. Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. Aliment Pharmacol Ther 2001;15:1737-1744.
4. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou' JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
5. Konig V, Hopf U, Neuhaus P, Bauditz J, Schmidt CA, Blumhardt G, et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994;58:553-559.
6. Seehofer D, Berg T. Prevention of hepatitis B recurrence after liver transplantation. Transplantation 2005;80:S120-124.
7. Tung BY, Kowdley KV. Hepatitis B and liver transplantation. Clin Infect Dis 2005;41:1461-1466.
8. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-210.
9. Fontana RJ, Keeffe EB, Carey W, Fried M, Reddy R, Kowdley KV, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002; 8:433-439.
10. Liaw YF, Sung JJ, Chow WG, Farrell G, Lee GZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.
11. Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, Zuckerman E, Sbeit W, Ackerman Z, et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int 2004;24: 547-551.
12. Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-1303.
13. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 2005;32:173-184.
14. Roznovsky L, Orságová I, Kloudová A, Mrázek J. Lamivudine therapy in patients with severe acute hepatitis B. Klin Mikrobiol Infekc Lek 2007;13:59-65.
15. Thompson AJ, Ayres A, Yuen L, Bartholomeusz A, Bowden DS, Iser DM, et al. Lamivudine resistance in patients with chronic hepatitis B: role of clinical and virological factors. J Gastroenterol Hepatol 2007;22:1078-1085.
16. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-528.
17. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008; 15:89-102.
18. Tsubota A. How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudinenaive patients with chronic hepatitis B virus infection? J Gastroenterol Hepatol 2006;21:1769-1771.
19. Rivkin AM. Adefovir dipivoxil in the treatment of chronic hepatitis B. Ann Pharmacother 2004;38:625-633.
20. Delaney WE 4th. Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. J Antimicrob Chemother 2007;59:827-832.
21. Dai CY, Chuang WL, Hsieh MY, Lee LP, Huang JF, Hou NJ, et al. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antiviral Res 2007;75:146-151.
22. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007;13:349-360.
23. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38:1419-1427.
24. O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992;14:104-111.
25. Brind A, Jiang J, Samuel D, Gigou M, Feray C, Bréchot C, et al. Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. J Hepatol 1997;26:228-235.
26. Repp R, Mance A, Bertram U, Niemann H, Gerlich WH, Lampert F. Persistent hepatitis B virus replication in mononuclear blood cells as a source of reinfection of liver transplants. Transplantation 1991;52:935.
27. Féray C, Zignego AL, Samuel D, Bismuth A, Reynes M, Tiollais P, et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. Transplantation 1990;49:1155-1158.
28. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005;11:402-409.
29. Ben-Ari Z, Ashur Y, Daudi N, Shmilovitz-Wiess H, Brown M, Sulkes J, et al. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation. Clin Transplant 2004;18:415-422.
30. Ben-Ari Z, Daudi N, Klein A, Sulkes J, Papo O, Mor E, et al. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. Am J Gastroenterol 2003;98:151-159.
31. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996;24:1327-1333.
32. Steinmüller T, Seehofer D, Rayes N, Müller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35:1528-1535.
33. Mohanty SR, Cotler SJ. Management of hepatitis B in liver transplant patients. J Clin Gastroenterol 2005;39:58-63.
34. Takaki A, Yagi T, Iwasaki Y, Sadamori H, Matsukawa H, Matsuda H, et al. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation 2007;83:231-233.
35. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Büschenfelde KH, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998;27:254-263.
36. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998;27:213-222.
37. Lo CM, Liu CL, Lau GK, Chan SC, Ng IO, Fan ST. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005;11:807-813.
38. Karatayli E, Karayalcin S, Karaaslan H, Kayhan H, Türkyilmaz AR, Sahin F, et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther 2007;12:761-768.
39. Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006;13:256-263.
40. Buff M, Mas A, Prieto M, Casafont F, González A, Miras M, et al. Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007;84:650-654.
41. Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006;12:253-258.
42. Buti M, Mas A, Prieto M, Casafont F, González A, Miras M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003;38:811-817.
43. Osborn MK, Han SH, Regev A, Bzowej NH, Ishitani MB, Tran TT, et al. Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol 2007;5:1454-1461.
44. Powell JJ, Apiratpracha W, Partovi N, Erb SR, Scudamore CH, Steinbrecher UP, et al. Subcutaneous administration of hepatitis B immune globulin in combination with lamivudine following orthotopic liver transplantation: effective prophylaxis against recurrence. Clin Transplant 2006;20:524-525.
45. Wang ZX, Ding GS, Fu H, Zhang JJ, Chen XS, Guo WY, et al. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. Hepatobiliary Pancreat Dis Int 2004;3:345-348.
46. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001;34:895-902.
47. Seehofer D, Rayes N, Naumann U, Neuhaus R, Müller AR, Tullius SG, et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001;72: 1381-1385.
48. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000;6:741-748.
49. Villeneuve Jp, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003;39:1085-1089.
50. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:283-290.
51. Toniutto P, Fumo E, Caldato M, Apollonio L, Perin A, Pirisi M. Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation. Transplantation 2004;77:472-473.
52. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ME, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816.
53. Lo CM, Cheung ST, Ng IO, Liu CL, Lai CL, Fan ST. Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. Liver Transpl 2004;10:557-563.
54. Palumbo E. Entecavir for chronic hepatitis B: a review. Ther Drug Monit 2008;30:1-4.
55. Zoulim F. Entecavir: a new treatment option for chronic hepatitis B. J Clin Virol 2006;36:8-12.
56. Amarapurkar DN. Telbivudine: a new treatment for chronic hepatitis B. World J Gastroenterol 2007;13:6150-6155.
57. Del Poggio P, Jamoletti C, Zaccanelli M. Tenofovir in chronic hepatitis B. Hepatology 2005;415:1199-1200.
58. Wong SN, Lok AS. Tenofovir disoproxil fumarate: role in hepatitis B treatment. Hepatology. 2006;44:309-313.
59. Neff GW, Nery J, Lau DT, O'Brien CB, Duncan R, Shire NJ, et al. Tenofovir therapy for lamivudine resistance following liver transplantation. Ann Pharmacother 2004; 38:1999-2004.
60. Taltavull TC, Chahri N, Verdura B, Gornals J, Lopez C, Casanova A, et al. Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results. Transpl Int 2005; 18:879-883.
61. Soejima Y, Shimada M, Taketomi A, Yoshizumi T, Uchiyama H, Ikegami T, et al. Successful living donor liver transplantation using a graft from a hepatitis B surface antigen-positive donor. Liver Int 2007;27:1282-1286.